In vivo tracking of macrophage activated killer cells to sites of metastatic ovarian carcinoma

Cancer Immunology, Immunotherapy

Volumn 56, Issue 2, 2007, Pages 155-163

  Ritchie, D ^a,c   Mileshkin, L ^a,c   Wall, D ^a   Bartholeyns, J ^b   Thompson, M ^a   Coverdale, J ^a   Lau, E ^a   Wong, J ^a   Eu, P ^a   Hicks, R J ^a,c   Prince, H M ^a,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b Immuno Designed Molecules   (France)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Immunotherapy; Macrophage; PET; Radiolabel

Indexed keywords

BISPECIFIC ANTIBODY; BISPECIFIC ANTIBODY MDX H210; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ARTICLE; CELL MIGRATION; CHILL; DRUG INFUSION; FEVER; HUMAN; HUMAN CELL; IMMUNOTHERAPY; IN VIVO STUDY; ISOTOPE LABELING; LYMPHADENOPATHY; MACROPHAGE ACTIVATION; METASTASIS; OVARY CARCINOMA; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; CARCINOMA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMMUNOTHERAPY; INDIUM RADIOISOTOPES; INFUSIONS, INTRAVENOUS; INFUSIONS, PARENTERAL; KILLER CELLS, LYMPHOKINE-ACTIVATED; MACROPHAGES; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY;

EID: 33751547951     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-006-0181-3     Document Type: Article

References (23)

1. Ribas A, Butterfield LH, Glaspy JA, Economou JS (2003) Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 21:2415-2432
2. Frangioni J, Hajjar R (2004) In vivo tracking of stem cells for clinical trials in cardiovascular disease. Circulation 110:3378-3384
3. Chokri M, Lopez M, Oleron C, Girard A, Martinache C, Siffert JC, Canepa S, Bartholeyns J (1992) Production of macrophages with potent antitumoral properties (MAK) by culture of monocytes in the presence of GM-CSF and 1,25 (OH)2 vitD3. Anticancer Res 12:2257-2260
4. Munn D, Cheung N (1990) Phagocytosis of tumor cells by human monocytes cultured in GM-CSF. J Exp Med 172:231-237
5. Fidler I, Kleinerman E (1992) Therapy of cancer metastases by systemic activation of macrophages. Res Immunol 144:284-287
6. Dumont S, Hartmann D, Poindron P, Faradji A, Oberling F, Bartholeyns J (1988) Control of the antitumoral activity of human macrophages produced in large amount in view of adoptive transfer. Eur J Cancer Clin Oncol 24:1691-1698
7. Baron-Bodo V, Doceur P, Lefebvre ML, Labroquère K, Defaye C, Cambouris C, Prigent D, Salcedo M, Boyer A, Nardin A (2005) Anti-tumor properties of human-activated macrophages produced in large scale for clinical application. Immunobiol 210:267-277
8. Faradji A, Bohbot A, Schmitt M, Siffert J, Dumont S, Wiesel M, Piemont Y, Eischen A, Bergerat J, Bartholeyns J, Poindron P, Witz JP, Oberling F (1994) Large scale isolation of human blood monocytes by continuous flow centrifugation leukapheresis and counterflow centrifugation elutriation for adoptive cellular immunotherapy in cancer patients. J Immunol Methods 174:297-309
9. Bartholeyns J, Lombard Y, Dumont S, Hartmann D, Chokri M, Giaimis J, Kaufmann S, Poindron P (1988) Immunotherapy of cancer: experimental approach with activated macrophages proliferating in culture. Cancer Detect Prev 12:413-420
10. Chokri M, Freudenberg M, Galanos C, Poindron P, Bartholeyns J (1989) Compared antitumoral effects of LPS, TNF, interferon and activated macrophages on experimental tumors. Synergism and tissue distribution Anticancer Res 9:1185-1190
11. Lopez M, Fechtenbaum J, David B, Martinache C, Chokri M, Canepa S, De Gramont A, Louvet C, Gorin I, Mortel O, Bartholeyns J (1992) Adoptive immunotherapy with activated macrophages grown in vitro from blood monocytes in cancer patients: a pilot study. J Immunotherapy 11:209-217
12. Faradji A, Bohbo A, Frost H, Schmitt-Goguel M, Siffert JC, Dufour P, Eber M, Lallot C, Wiesel ML, Bergerat JP, Oberling F (1991) Phase I study of liposomal PTP-PE-activated autologous monocytes administered intraperitoneally to patients with peritoneal carcinomatosis. J Clin Oncol 9:1251-1260
13. Valone F, Kaufman P, Guyre P (1995) Phase I trial of bispecific antibody MDX-H210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HERa neu. J Clin Oncol 13:2281-2292
14. Mano MS, Awada A, Di Leo A, Durbecq V, Paesmans M, Cardoso F, Larsimont D, Piccart M (2004) Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma. Gynecol Oncol 92(3):887-895
15. Curnow RT (1997) Clinical experience with CD64-directed immunotherapy. An overview. Cancer Immunol Immunother 45:210-215
16. de Gramont A, Gangji D, Louvet C, Garcia ML, Tardy D, Romet-Lemonne JL (2002) Adoptive immunotherapy of ovarian carcinoma. Gynecol Oncol 86:102-103
17. Chokri M, Lallot C, Ebert M, Poindron P, Bartholeyns J (1990) Biodistribution of indium-labelled macrophages in mice bearing solid tumors. Int J Immunother 6:79-84
18. Forstrom LA, Mullan BP, Hung JC, Lowe VJ, Thorson LM (2000) 18F-FDG labelling of human leucocytes. Nucl Med Commun 21:691-694
19. Hofmann M, Wollert KC, Meyer GP, Menke A, Arseniev L, Hertenstein B, Ganser A, Knapp WH, Drexler H (2005) Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation 111(17):2198-2202
20. Wall DM, Prince HM (2003) Regulation of cellular therapies: the Australian perspective. Cytotherapy 5(4):284-288
21. Adonai N, Nguyen KN, Walsh J, Iyer M, Toyokuni T, Phelps ME, McCarthy T, McCarthy DW, Gambhir SS (2002) Ex vivo cell labeling with 64Cu-pyruvaldehyde- bis(N4-methylthiose-micarbazone) for imaging cell trafficking in mice with positron-emission tomography. Proc Natl Acad Sci USA 99:3030-3035
22. Quillien V, Moisan A, Lesimple T, Leberre C, Toujas L (2001) Biodistribution of 111indium-labeled macrophages infused intravenously in patients with renal carcinoma. Cancer Immunol Immunother 50(9):477-482
23. Lesimple T, Moisan A, Carsin A, Ollivier I, Mousseau M, Meunier B, Leberre C, Collet B, Quillien V, Drenou B, Lefeuvre-Plesse C, Chevrant-Breton J, Toujas L (2003) Injection by various routes of melanoma antigen-associated macrophages: biodistribution and clinical effects. Cancer Immunol Immunother 52(7):438-444